In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

Question

In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because: (A) Genetically engineered lymphocytes are not immortal cells. (B) Retroviral vector is introduced into these lymphocytes. (C) Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages (D) Lymphocytes from patient's blood are grown in culture, outside the body.

Tardigrade Admin · Accepted Answer

Correct answer is (a) Genetically engineered lymphocytes are not immortal cells.

Q. In gene therapy of Adenosine Deaminase (ADA) deficiency, the patient requires periodic infusion of genetically engineered lymphocytes because:

Genetically engineered lymphocytes are not immortal cells.

Retroviral vector is introduced into these lymphocytes.

Gene isolated from marrow cells producing ADA is introduced into cells at embryonic stages

Lymphocytes from patient's blood are grown in culture, outside the body.

Correct answer is (a) Genetically engineered lymphocytes are not immortal cells.